Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy
Author:
Affiliation:
1. Disarm Therapeutics, a wholly owned subsidiary of Eli Lilly & Co., Cambridge MA 02142, USA
2. Evotec (UK), Abingdon, Oxfordshire, OX14 4RZ, UK
3. Evotec SE, 22419 Hamburg, Germany
4. Evotec France SAS, 31036 Toulouse, France
Abstract
Funder
Disarm Therapeutics
Publisher
Oxford University Press (OUP)
Subject
Clinical Neurology
Link
https://academic.oup.com/brain/advance-article-pdf/doi/10.1093/brain/awab184/41090530/awab184.pdf
Reference47 articles.
1. The ‘dying back’ process. A common denominator in many naturally occurring and toxic neuropathies;Cavanagh;Arch Pathol Lab Med,1979
2. SARM1 activation triggers axon degeneration locally via NAD+ destruction;Gerdts;Science,2015
3. The SARM1 toll/interleukin-1 receptor domain possesses intrinsic NAD+ cleavage activity that promotes pathological axonal degeneration;Essuman;Neuron,2017
4. Axons matter: The promise of treating neurodegenerative disorders by targeting SARM1-mediated axonal degeneration;Krauss;Trends Pharmacol Sci,2020
5. Programmed axon degeneration: from mouse to mechanism to medicine;Coleman;Nat Rev Neurosci,2020
Cited by 76 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Preparation of Viable Human Neurites for Neurobiological and Neurodegeneration Studies;Cells;2024-01-27
2. The Role of NMNAT2/SARM1 in Neuropathy Development;Biology;2024-01-22
3. Genetic ablation of Sarm1 attenuates expression and mislocalization of phosphorylated TDP-43 after mouse repetitive traumatic brain injury;Acta Neuropathologica Communications;2023-12-20
4. NMN: The NAD precursor at the intersection between axon degeneration and anti-ageing therapies;Neuroscience Research;2023-12
5. NAD+, Axonal Maintenance, and Neurological Disease;Antioxidants & Redox Signaling;2023-12-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3